Francesco Passamonti

38.9k total citations · 8 hit papers
316 papers, 17.3k citations indexed

About

Francesco Passamonti is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Francesco Passamonti has authored 316 papers receiving a total of 17.3k indexed citations (citations by other indexed papers that have themselves been cited), including 284 papers in Genetics, 213 papers in Hematology and 100 papers in Molecular Biology. Recurrent topics in Francesco Passamonti's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (261 papers), Chronic Myeloid Leukemia Treatments (107 papers) and Acute Myeloid Leukemia Research (100 papers). Francesco Passamonti is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (261 papers), Chronic Myeloid Leukemia Treatments (107 papers) and Acute Myeloid Leukemia Research (100 papers). Francesco Passamonti collaborates with scholars based in Italy, United States and United Kingdom. Francesco Passamonti's co-authors include Mario Cazzola, Alessandro M. Vannucchi, Elisa Rumi, Ayalew Tefferi, Francisco Cervantes, Róbert Královics, Radek C. Skoda, Mario Lazzarino, Ralph Tiedt and André Tichelli and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Francesco Passamonti

307 papers receiving 17.0k citations

Hit Papers

A Gain-of-Function Mutation of JAK2 in Myeloproliferative... 2005 2026 2012 2019 2005 2008 2010 2009 2005 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
    2005 2.6k citations Francesco Passamonti, Mario Cazzola et al. profile →
  2. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
    2008 830 citations Francisco Cervantes, Francesco Passamonti et al. Blood profile →
  3. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
    2010 657 citations Naseema Gangat, Domenica Caramazza et al. Journal of Clinical Oncology profile →
  4. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
    2009 623 citations Francesco Passamonti, Francisco Cervantes et al. Blood profile →
  5. Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making
    2005 618 citations Francesco Passamonti, Luca Arcaini et al. Journal of Clinical Oncology profile →
  6. Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
    2015 594 citations Alessandro M. Vannucchi, Jean‐Jacques Kiladjian et al. profile →
  7. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
    2014 366 citations Ayalew Tefferi, Rhett P. Ketterling et al. Leukemia profile →
  8. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
    2015 340 citations Animesh Pardanani, Claire Harrison et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Francesco Passamonti Italy 59 14.9k 11.3k 8.6k 5.8k 1.6k 316 17.3k
Claire Harrison United Kingdom 58 12.8k 0.9× 9.4k 0.8× 7.7k 0.9× 5.1k 0.9× 1.2k 0.7× 452 15.0k
Alessandro M. Vannucchi Italy 78 19.2k 1.3× 14.8k 1.3× 12.1k 1.4× 7.7k 1.3× 1.6k 1.0× 549 23.0k
Francisco Cervantes Spain 64 15.8k 1.1× 14.5k 1.3× 7.6k 0.9× 7.1k 1.2× 1.5k 0.9× 321 20.0k
Jean‐Jacques Kiladjian France 49 9.4k 0.6× 7.4k 0.7× 5.4k 0.6× 4.0k 0.7× 1.0k 0.7× 381 12.0k
Curtis A. Hanson United States 63 10.9k 0.7× 8.7k 0.8× 5.3k 0.6× 2.8k 0.5× 1.4k 0.9× 393 14.7k
Mario Lazzarino Italy 48 5.0k 0.3× 5.6k 0.5× 2.6k 0.3× 1.3k 0.2× 2.4k 1.5× 236 9.8k
Tamás Masszi Hungary 30 2.3k 0.2× 3.8k 0.3× 2.3k 0.3× 948 0.2× 2.3k 1.5× 188 6.1k
Sigurður Y. Kristinsson Sweden 46 2.6k 0.2× 3.9k 0.3× 2.2k 0.3× 597 0.1× 1.6k 1.0× 142 6.0k
Luca Arcaini Italy 49 4.9k 0.3× 2.4k 0.2× 1.6k 0.2× 953 0.2× 2.3k 1.5× 223 8.7k
Raymond L. Comenzo United States 44 2.1k 0.1× 2.9k 0.3× 6.7k 0.8× 909 0.2× 2.4k 1.5× 230 8.3k

Countries citing papers authored by Francesco Passamonti

Since Specialization
Citations

This map shows the geographic impact of Francesco Passamonti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesco Passamonti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesco Passamonti more than expected).

Fields of papers citing papers by Francesco Passamonti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesco Passamonti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesco Passamonti. The network helps show where Francesco Passamonti may publish in the future.

Co-authorship network of co-authors of Francesco Passamonti

This figure shows the co-authorship network connecting the top 25 collaborators of Francesco Passamonti. A scholar is included among the top collaborators of Francesco Passamonti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesco Passamonti. Francesco Passamonti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Passamonti, Francesco, et al.. (2025). Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib. Future Oncology. 21(5). 579–591. 2 indexed citations
2.
Mora, Barbara, et al.. (2025). CALR -mutated myeloproliferative neoplasms. Leukemia & lymphoma. 66(7). 1198–1210. 2 indexed citations
3.
Guglielmelli, Paola, Arianna Ghirardi, Alessandra Carobbio, et al.. (2025). Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real‐world ERNEST‐2 registry. HemaSphere. 9(2). e70072–e70072.
4.
Breccia, Massimo, Francesca Palandri, Francesco Passamonti, et al.. (2024). The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real‐world study on AIFA monitoring registries. British Journal of Haematology. 206(1). 172–179. 1 indexed citations
5.
Harrison, Claire, Alessandro M. Vannucchi, Christian Récher, et al.. (2024). Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2. Advances in Therapy. 41(9). 3722–3735. 7 indexed citations
6.
Kuykendall, Andrew, Somedeb Ball, Barbara Mora, et al.. (2024). Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib. JCO Precision Oncology. 8(8). e2300593–e2300593. 3 indexed citations
7.
Harrison, Claire, Ruben A. Mesa, Moshe Talpaz, et al.. (2024). Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet Haematology. 11(10). e729–e740. 11 indexed citations
8.
Bianchi, Paola, Cristina Vercellati, Elisa Fermo, et al.. (2024). Toward the Creation of Diagnostic Algorithms for Congenital Hemolytic Anemia Using Advanced Parameters from Modern Hematology Analyzers. Blood. 144(Supplement 1). 1086–1086.
9.
Pemmaraju, Naveen, Jacqueline S. Garcia, Andrew C. Perkins, et al.. (2023). New era for myelofibrosis treatment with novel agents beyond Janus kinase‐inhibitor monotherapy: Focus on clinical development of BCL‐XL/BCL‐2 inhibition with navitoclax. Cancer. 129(22). 3535–3545. 12 indexed citations
10.
Pemmaraju, Naveen, Srđan Verstovšek, Ruben A. Mesa, et al.. (2022). Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer. 128(13). 2420–2432. 44 indexed citations
11.
12.
Mascarenhas, John, Francesco Passamonti, Kate Burbury, et al.. (2021). The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Advances. 6(4). 1162–1174. 16 indexed citations
13.
Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2020). Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. American Journal of Hematology. 95(6). 594–603. 104 indexed citations
14.
Cassinat, Bruno, Barbara Mora, Emmanuelle Verger, et al.. (2020). Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Advances. 4(15). 3708–3715. 30 indexed citations
15.
Cassinotti, A., Francesco Passamonti, & Sergio Segato. (2020). CELL THERAPY IN INFLAMMATORY BOWEL DISEASE. Pharmacological Research. 163. 105247–105247. 14 indexed citations
16.
Tefferi, Ayalew, Mythri Mudireddy, Francesco Mannelli, et al.. (2018). Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 32(5). 1200–1210. 93 indexed citations
17.
Tefferi, Ayalew, Francesco Passamonti, Tiziano Barbui, et al.. (2013). Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. Blood. 122(21). 394–394. 24 indexed citations
18.
Gangat, Naseema, Domenica Caramazza, Rakhee Vaidya, et al.. (2010). DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. Journal of Clinical Oncology. 29(4). 392–397. 657 indexed citations breakdown →
19.
Noris, Patrizia, Catherine Klersy, Marco Zecca, et al.. (2009). Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. Journal of Thrombosis and Haemostasis. 7(12). 2131–2136. 73 indexed citations
20.
Brazzelli, Valeria, Francesca Prestinari, Tania Barbagallo, et al.. (2006). A long‐term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. Journal of the European Academy of Dermatology and Venereology. 21(3). 384–387. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claire Harrison Breakdown of academic impact, for papers by Alessandro M. Vannucchi Breakdown of academic impact, for papers by Francisco Cervantes Breakdown of academic impact, for papers by Jean‐Jacques Kiladjian Breakdown of academic impact, for papers by Curtis A. Hanson Breakdown of academic impact, for papers by Mario Lazzarino Breakdown of academic impact, for papers by Tamás Masszi Breakdown of academic impact, for papers by Sigurður Y. Kristinsson Breakdown of academic impact, for papers by Luca Arcaini Breakdown of academic impact, for papers by Raymond L. Comenzo
Rankless by CCL
2026